Biogen Alzheimer’s data won’t sway believers or doubters either way

The upshot of Biogen’s aducanumab data is that the robustness of the compound’s efficacy remains in doubt. The CTAD presentation gave enough grist for believers to continue believing and skeptics to keep on doubting.

Aducanumab data presented by Biogen Inc. (NASDAQ:BIIB) at the Clinical Trials in Alzheimer’s Disease (CTAD) meeting in San Diego on Thursday buttressed the company’s hypothesis that Alzheimer’s disease patients treated at the highest dose for longer are more likely to achieve clinical benefit with the anti-β amyloid mAb, but the findings fell short of resolving questions about the opposite results of the Phase III ENGAGE and EMERGE trials...